Ep. 178 ASCO 2024: Game-Changing GU Oncology Updates in Bladder and Kidney Cancers with Dr. Sumanta Pal and Dr. Petros Grivas
Jul 16 2024
Length: 56 mins
Podcast

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Add to Cart failed.

Please try again later

Please try again later

Please try again later

Please try again

Please try again

Please try again

Listen for free

View show details

Summary
Stay up-to-date on the latest advancements and treatment strategies in the field of genitourinary oncology. In this episode of BackTable Urology, guest host Dr. Bogdana Schmidt, a urologic oncologist from the University of Utah, discusses takeaways from ASCO 2024 with Dr. Petros Grivas from Fred Hutchinson Cancer Center and Dr. Sumanta (Monty) Pal from City of Hope. --- CHECK OUT OUR SPONSOR Siemens Healthineers Theranostics https://www.siemens-healthineers.com/en-us/clinical-specialities/theranostics --- SYNPOSIS The conversation initially focuses on advanced urothelial carcinoma and the EV302 trial, discussing detailed insights from the quality-of-life results presented at ASCO. The experts offer relevant clinical perspectives for modern metastatic urothelial carcinoma management, focusing on pembrolizumab plus enfortumab vedotin. Further, they delve into breaking biomarker research at ASCO, including KIM-1 in adjuvant renal cell carcinoma (RCC) therapy and the HIF-2 inhibitor DFF332 for chromophobe RCC. --- TIMESTAMPS 00:00 - Introduction 03:42 - Pembrolizumab and Enfortumab Vedotin Trial Insights 07:43 - Future Trials and Treatment Strategies 21:27 - Javelin Bladder 100 Trial Discussion 32:05 - Growth Factor Use 36:21 - Future Directions of Biomarkers 38:55 - Kidney Cancer Biomarker Trials 53:40 - Concluding Thoughts

Show more Show less

Average customer ratings

No Reviews are Available

Report a review on Amazon